Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 6/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16376634 | 1.00 | KCNH2 (0.36) | KCNH2CCR2CYP2D6DRD2DRD3 | |
| SCHEMBL9926452 | 1.00 | KCNH2 (0.36) | KCNH2CCR2CYP2D6DRD2DRD3 | |
| SCHEMBL16376638 | 0.94 | CHRM5 (0.34) | KCNH2CCR2CYP2D6DRD2DRD3 | |
| SCHEMBL18844639 | 0.94 | CHRM5 (0.34) | KCNH2CCR2CYP2D6DRD2DRD3 | |
| SCHEMBL2737413 | 0.87 | HRH3 (0.38) | KCNH2 | |
| SCHEMBL2737395 | 0.87 | HRH3 (0.38) | KCNH2 | |
| SCHEMBL11997995 | 0.87 | HRH3 (0.38) | KCNH2 | |
| SCHEMBL20942482 | 0.84 | KCNH2 (0.35) | KCNH2CCR2CYP2D6DRD2DRD3 | |
| SCHEMBL18270438 | 0.84 | KCNH2 (0.35) | KCNH2CCR2CYP2D6DRD2DRD3 | |
| SCHEMBL16376644 | 0.83 | HRH3 (0.39) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| EP-3544971-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210317105-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200361906-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | US | disclosed |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | KCNH2 3440/4885CCR2 1477/4885CYP2D6 3456/4885 |
| US-20210317105-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | KCNH2 3213/4885CCR2 717/4885CYP2D6 901/4885 |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | KCNH2 4654/4885CCR2 3212/4885CYP2D6 1111/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | KCNH2 3146/4885CCR2 3031/4885CYP2D6 1699/4885 |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | KCNH2 4654/4885CCR2 3212/4885CYP2D6 1111/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | KCNH2 4663/4885CCR2 706/4885CYP2D6 4337/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | KCNH2 3146/4885CCR2 3031/4885CYP2D6 1699/4885 |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | CDK12, CDK1, CDK13 | KCNH2 3213/4885CCR2 717/4885CYP2D6 901/4885 |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | KCNH2 4389/4885CCR2 3604/4885CYP2D6 279/4885 |
| US-20200361906-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | KCNH2 3213/4885CCR2 717/4885CYP2D6 901/4885 |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | KCNH2 4654/4885CCR2 3212/4885CYP2D6 1111/4885 |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | KCNH2 4654/4885CCR2 3212/4885CYP2D6 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.